1. Home
  2. TRIN vs IMTX Comparison

TRIN vs IMTX Comparison

Compare TRIN & IMTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Trinity Capital Inc.

TRIN

Trinity Capital Inc.

HOLD

Current Price

$17.43

Market Cap

1.6B

Sector

Finance

ML Signal

HOLD

Logo Immatics N.V.

IMTX

Immatics N.V.

HOLD

Current Price

$9.17

Market Cap

1.4B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
TRIN
IMTX
Founded
2007
N/A
Country
United States
Germany
Employees
109
407
Industry
Finance/Investors Services
Biotechnology: Biological Products (No Diagnostic Substances)
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
1.6B
1.4B
IPO Year
N/A
N/A

Fundamental Metrics

Financial Performance
Metric
TRIN
IMTX
Price
$17.43
$9.17
Analyst Decision
Buy
Strong Buy
Analyst Count
5
6
Target Price
$16.00
$19.00
AVG Volume (30 Days)
952.9K
336.8K
Earning Date
05-06-2026
05-13-2026
Dividend Yield
12.61%
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
$30.41
N/A
Revenue Next Year
$10.00
$25.91
P/E Ratio
$7.18
N/A
Revenue Growth
N/A
N/A
52 Week Low
$14.13
$5.05
52 Week High
$18.12
$12.41

Technical Indicators

Market Signals
Indicator
TRIN
IMTX
Relative Strength Index (RSI) 52.64 42.05
Support Level $16.61 N/A
Resistance Level $18.10 $10.67
Average True Range (ATR) 0.33 0.47
MACD -0.05 -0.05
Stochastic Oscillator 43.07 46.86

Price Performance

Historical Comparison
TRIN
IMTX

About TRIN Trinity Capital Inc.

Trinity Capital Inc is an internally managed, closed-end, non-diversified management investment company. Its investment objective is to generate current income and, to a lesser extent, capital appreciation through investments across five distinct vertical markets. The company is focused on achieving its investment objective by operating as a specialty lending company that provides debt, including loans, equipment financings, and asset-based lending, to growth-oriented companies, including institutional investor-backed companies. Its investment portfolio mainly comprises private companies that have begun to have success selling their products to the market and need additional capital to expand their operations and sales.

About IMTX Immatics N.V.

Immatics NV is a clinical-stage biotechnology company engaged in the research and development of T-cell redirecting immunotherapies for the treatment of cancer patients. The company earns revenue through strategic collaboration agreements with third-party pharmaceutical and biotechnology companies. The company derives its maximum revenue from United States.

Share on Social Networks: